Skip to main content

Understanding Breast Density: What Your Mammogram Means

If your mammogram report mentions that you have dense breasts, you are not alone — this is a common finding in women who attend breast screening. Breast density refers to the proportion of glandular and fibrous tissue in your breasts compared to fatty tissue. It affects both how clearly a mammogram can detect changes, and your overall risk of developing breast cancer. This article explains what breast density means, how it is measured, and what practical steps you can take.

Schematic illustration showing the four BI-RADS breast density categories A through D on a mammogram — for educational purposes only, not a real clinical scan
Schematic illustration of the four BI-RADS breast density categories (A–D) on a mediolateral oblique (MLO) mammogram view. Density patterns are schematically drawn on a single mammogram image for educational purposes only and do not represent individual patient scans. Image: Mr Justin James.

1. What is breast density?

Your breasts contain glandular tissue (milk-producing lobules and ducts), supportive fibrous tissue, and fatty tissue. The balance between these is what we call breast density. Dense breasts have a higher proportion of glandular and fibrous tissue relative to fat.

Breast density can only be seen on a mammogram — you cannot feel it yourself, and it has nothing to do with breast size or how your breasts look. On a mammogram, dense tissue appears white and fatty tissue appears dark. Understanding your density matters because it influences both your cancer risk and how easy it is to spot a cancer on a mammogram.

2. How is breast density classified?

Radiologists grade density using the BI-RADS (Breast Imaging Reporting and Data System) scale — a standard international system with four categories:

  • Category A — Almost entirely fatty: very little dense tissue
  • Category B — Scattered density: mostly fatty, with some dense areas
  • Category C — Heterogeneously dense: many dense areas that may obscure small changes
  • Category D — Extremely dense: the breast is almost entirely dense tissue

In Australia, BreastScreen notifies all screened women of their density category. Categories C and D are considered dense breasts. If you are unsure which category applies to you, check your most recent BreastScreen result letter or speak with your GP.

3. Does breast density increase my cancer risk?

Yes — breast density is an independent risk factor for breast cancer. Women with heterogeneously dense breasts (Category C) have 1.6 times the average population risk of breast cancer, and women with extremely dense breasts (Category D) have 2.6 times the average population risk. These figures are relative to Category B, which represents the general population risk.

Dense tissue also causes what is called the masking effect: because both dense tissue and cancer appear white on a mammogram, a small cancer can be hidden within dense areas. This means a normal mammogram result in a woman with dense breasts does not guarantee all is well. Being aware of this — and reporting any new breast changes to your doctor promptly — is important.

4. What causes breast density?

Breast density is largely determined by genetics and tends to run in families. It naturally decreases after menopause as glandular tissue is replaced by fat, though some women retain dense breasts well into later life. Several factors can influence density:

  • Age — density decreases as you get older
  • Hormones — premenopausal breasts are denser due to oestrogen and progesterone
  • Hormone Replacement Therapy (HRT) — combined HRT can increase density in some women
  • Body weight — women with a higher BMI tend to have less dense breasts
  • Genetics — density is strongly inherited

Density can also fluctuate slightly through the menstrual cycle or with pregnancy and breastfeeding.

5. What are my options if I have dense breasts?

Dense breasts alone are not a reason to panic, but they are worth discussing with your doctor. Options to consider include:

Supplemental screening: Women with dense breasts may benefit from additional imaging alongside their regular mammogram. Breast ultrasound, 3D mammography (digital breast tomosynthesis), or breast MRI are available depending on your individual risk profile and your doctor’s recommendation. Each has benefits and limitations that your doctor can explain.

Formal risk assessment: A specialist can review your overall breast cancer risk, taking into account your density, family history, and other factors. This helps determine the most appropriate screening plan for you personally.

6. What should I do next?

If BreastScreen has told you that you have dense breasts, the most important first step is to speak with your GP. They can review your overall risk, recommend further assessment if needed, and help you decide whether supplemental screening is appropriate.

Continue attending your regular BreastScreen mammograms — they remain valuable even in dense breasts and detect many cancers that would otherwise be missed. Stay breast aware, and report any new lumps, skin changes, nipple discharge, or breast pain to your doctor promptly.

If you would like a specialist opinion, Mr Justin James is happy to discuss your situation. Please book a consultation through our Contact page.

Key Takeaways

  • Breast density reflects the amount of glandular and fibrous tissue compared to fat — it can only be assessed on a mammogram, not by feel
  • Dense breasts (BI-RADS Category C or D) are a common finding in women who attend breast screening
  • High breast density is an independent risk factor for breast cancer, increasing risk 1.6-fold (Category C) and 2.6-fold (Category D) relative to Category B
  • Dense tissue can mask cancers on a mammogram — a normal result does not guarantee no cancer is present
  • Talk to your GP if you have dense breasts; additional screening or a risk assessment may be recommended

Clinical Notes for Referring Doctors

  • Dense breasts (BI-RADS c or d) affect ~43% of women aged 40–74 years; relative to BI-RADS b (population reference), category c carries 1.6-fold and category d 2.6-fold higher risk; compared to category a (fatty breasts), category d risk is approximately 4.6-fold (McCormack meta-analysis, RR 4.64, 95% CI 3.64–5.91). [5,8]
  • Masking effect: mammographic sensitivity is approximately 90% for BI-RADS a/b, 84% for category c, and 64% for category d — a normal mammogram does not exclude malignancy in dense breasts. [8]
  • Supplemental screening — incremental cancer detection per 1,000 women screened: MRI ~16, CEM ~16, ultrasound ~4, DBT ~1.7. MRI and CEM are the most sensitive modalities but carry higher false-positive rates, access limitations, and out-of-pocket costs; DBT and US are less sensitive. [8]
  • MBS-rebatable breast MRI (Item 63464): requires age <60 years AND lifetime risk >30% (or 10-year absolute risk >5%), calculated using a validated tool (iPrevent or Tyrer-Cuzick incorporating density); specialist referral required. No MBS item covers supplemental screening in average- or moderate-risk women with dense breasts. CEM has no MBS item; ultrasound is MBS-covered where clinically indicated (Item 55076). [8]
  • Density is incorporated into Tyrer-Cuzick v8 and BOADICEA. For women with BI-RADS c or d and additional risk factors (first-degree relative with breast cancer, atypical hyperplasia, or prior chest irradiation), calculate overall risk using iPrevent or Tyrer-Cuzick to determine MBS Item 63464 eligibility; consider referral to familial cancer services for high-risk patients. [3,4,8]
  • Combined oestrogen-progestogen MHT increases mammographic density; oestrogen-only therapy does not significantly affect density. Counsel women regarding the impact of combined MHT on mammographic sensitivity; optimal mammogram timing for sequential regimens is during the progestogen-free phase. [5]
  • Chemoprevention (tamoxifen premenopausal, anastrozole postmenopausal) reduces breast cancer incidence in high-risk women but has not been shown to reduce breast cancer mortality; uptake remains low largely due to adverse effects. Shared decision-making is essential when discussing preventive medications with high-risk patients. [9]

Further Information and Useful Links

Related Articles

You may also find these articles from Mr Justin James useful:

References

  1. Monticciolo DL, et al. Breast Cancer Screening for Women at Higher-Than-Average Risk. J Am Coll Radiol. 2023;20(9):902–914. DOI: 10.1016/j.jacr.2023.04.002
  2. Freer PE. Mammographic breast density: impact on breast cancer risk and implications for screening. Radiographics. 2015;35(2):302–315. DOI: 10.1148/rg.352140106
  3. Harkness EF, et al. Risk-based breast cancer screening strategies in women. Best Pract Res Clin Obstet Gynaecol. 2019;65:3–17. DOI: 10.1016/j.bpobgyn.2019.11.005
  4. Acciavatti RJ, et al. Beyond Breast Density: Risk Measures for Breast Cancer in Multiple Imaging Modalities. Radiology. 2023;306(3):e222575. DOI: 10.1148/radiol.222575
  5. Nazari SS, Mukherjee P. An overview of mammographic density and its association with breast cancer. Breast Cancer. 2018;25(3):259–267. DOI: 10.1007/s12282-018-0857-5
  6. BreastScreen Australia. GP Guidance: Breast Density. Canberra: Australian Government; November 2025.
  7. Aliberti GM, Weinstein AR, Schonberg MA. When Risk Scores Meet Mammography. JAMA Intern Med. Published online June 22, 2026. DOI: 10.1001/jamainternmed.2026.2420

Disclaimer: This article is general information only and is not a substitute for individual medical advice. Please consult Mr Justin James or your treating doctor about your specific situation.

Leave a Reply